Intas Pharma launches leukaemia drug Azadine-O
24 September 2021 | News
The drug will bridge a long-pending unmet need in cancer therapy
Image Credit: Shutterstock
Ahmedabad-based Intas Pharmaceuticals has launched oral azacitidine in India under the brand name Azadine-O.
Oral Azacitidine is approved for use in maintenance therapy for adult patients with Acute Myeloid Leukaemia.
It is the first drug that will improve survival by almost ten months and bridge a long-pending unmet need in cancer therapy.
Prof (Dr) MB Agarwal, shared his views about the launch, saying, "Oral Azacitidine will prove to be extremely useful for AML patients. There was a dire need for this drug. It shall significantly improve survival and quality of life of patients."
